Scholarlink

Background <p>The optimal interval between neoadjuvant chemotherapy (NAC) and breast surgery remains unclear. We evaluated whether time to surgery (TTS) affects 30-day postoperative complications.</p> Patients and Methods <p>Review&#xa0;was performed of all&#xa0;women undergoing mastectomy with or without reconstruction following NAC at a single institution&#xa0;between 2014–2024. The 30-day postoperative complications were analyzed by TTS using chi-squared tests for univariate analysis and logistic regression for multivariable analysis.</p> Results <p>A total of 862 patients were identified with mastectomy following NAC with a median age of 49 (range 22–86) years, and 30-day complications occurred in 54 patients (6.3%, 95% CI 4.8–8.1%), including hematoma (<i>n</i> = 11), surgical site infection (<i>n</i> = 19), necrosis (<i>n</i> = 19), thromboembolism (<i>n</i> = 3), and <i>C</i>. <i>difficile</i> infection (<i>n</i> = 2). 30-day surgical complications were not different between those treated with immunotherapy (4.3%) versus without (6.4%, <i>p</i> = 0.79). TTS was 20-62 days in 90% of patients.&#xa0;Median TTS was 32 (IQR 27–40) days, which did not differ between patients with and without a complication (<i>p</i> = 0.85). Adjusting for age, smoking, type of mastectomy, and surgery year on multivariable analysis, there was no significant association between TTS and 30-day surgical complications (adjusted OR for TTS ≤ 32 days versus &gt; 32 days 1.30, 95% CI 0.75–2.29, <i>p</i> = 0.35). Recurrence-free survival was similar between patients with TTS ≤ 32 days versus &gt; 32 days, both&#xa0;overall (78.9% versus 80.7% at 5 years, <i>p</i> = 0.29) and&#xa0;when stratified by residual cancer burden and tumor biology.</p> Conclusions <p>TTS between 3 and 9 weeks after NAC was not associated with higher 30-day clinically significant complications. These findings support reasonable scheduling flexibility, but they do not establish safety of very early or delayed surgery outside this window.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Time Interval Between Neoadjuvant Chemotherapy Completion and Mastectomy is Not Associated with 30-Day Complication Rate

  • 期刊论文

  • 发表日期：

    2026年7月23日

查看全文
  • Lilia G. Lunt,
  • Tanya L. Hoskin,
  • Amy C. Degnim,
  • Carrie A. Olson,
  • Milissa M. Klebe,
  • Rachel E. Marden,
  • Judy C. Boughey

摘要

Background

The optimal interval between neoadjuvant chemotherapy (NAC) and breast surgery remains unclear. We evaluated whether time to surgery (TTS) affects 30-day postoperative complications.

Patients and Methods

Review was performed of all women undergoing mastectomy with or without reconstruction following NAC at a single institution between 2014–2024. The 30-day postoperative complications were analyzed by TTS using chi-squared tests for univariate analysis and logistic regression for multivariable analysis.

Results

A total of 862 patients were identified with mastectomy following NAC with a median age of 49 (range 22–86) years, and 30-day complications occurred in 54 patients (6.3%, 95% CI 4.8–8.1%), including hematoma (n = 11), surgical site infection (n = 19), necrosis (n = 19), thromboembolism (n = 3), and C. difficile infection (n = 2). 30-day surgical complications were not different between those treated with immunotherapy (4.3%) versus without (6.4%, p = 0.79). TTS was 20-62 days in 90% of patients. Median TTS was 32 (IQR 27–40) days, which did not differ between patients with and without a complication (p = 0.85). Adjusting for age, smoking, type of mastectomy, and surgery year on multivariable analysis, there was no significant association between TTS and 30-day surgical complications (adjusted OR for TTS ≤ 32 days versus > 32 days 1.30, 95% CI 0.75–2.29, p = 0.35). Recurrence-free survival was similar between patients with TTS ≤ 32 days versus > 32 days, both overall (78.9% versus 80.7% at 5 years, p = 0.29) and when stratified by residual cancer burden and tumor biology.

Conclusions

TTS between 3 and 9 weeks after NAC was not associated with higher 30-day clinically significant complications. These findings support reasonable scheduling flexibility, but they do not establish safety of very early or delayed surgery outside this window.